ClinicalTrials.gg
CompletedNCT07620951Updated Sep 22, 2026

Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China

A Phase 1 interventional study of [14C]Zorifertinib Oral Formulation in EGFR Mutant Advanced Non-small Cell Lung Cancer and Central Nervous System (CNS) Metastases, sponsored by Alpha Biopharma (Jiangsu) Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Alpha Biopharma (Jiangsu) Co., Ltd. · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
398th of 403
6 · median 90
Started
2026
with 63 others
Phase 1
93 of 487
47 open now
Registered
457th of 487
by date

Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 398th largest by enrollment of the 403 interventional ones that give a count, is one of 64 that started in 2026, is one of 93 in phase 1, and was the 457th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

219 more — sign in →

All 224 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of [14C]Zorifertinib in healthy Chinese adult male participants. The study includes a screening period (Day -14 to Day -1) and a dosing and observation period (Day 1 to Day 14). Blood, urine, and feces samples will be collected to measure radioactivity, drug concentrations, and metabolites. Safety will be assessed by adverse events, vital signs, laboratory tests, 12-lead ECG, and ophthalmic examinations. The target total radioactivity recovery is ≥90% of the administered dose.

03

Conditions studied

  • EGFR Mutant Advanced Non-small Cell Lung Cancer
  • Central Nervous System (CNS) Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese males;
  2. Age at the time of signing the form: 18-45 years (inclusive);
  3. (BMI) ranging from 19-26 kg/m2 (inclusive), with a body weight of no less than 50 kg;
  4. Fully understand the purpose and requirements of this study and voluntarily sign the informed consent form;
  5. Be able to communicate well with the investigators and complete the trial according to the protocol.
  6. The 14C content in plasma and urine samples obtained during screening are within general environmental 14C background levels. Directly analyzed plasma samples must have values ≤150 pMC, and urine samples containing petroleum-based carbon carriers must have values ≤50 pMC.

Exclusion criteria

Exclusion Criteria:

Ancillary Examinations:

  1. Abnormal findings from comprehensive physical examination, vital signs, laboratory tests (hematology, blood biochemistry, coagulation function, urinalysis, routine stool + occult blood, thyroid function), 12-lead , chest X-ray (posteroanterior view), abdominal ultrasound, digital rectal examination, etc., that are judged by the investigator as .
  2. Resting interval (Fridericia correction, QTcF = QT/RR1/3) obtained from 12-lead ECG >450 ms in males, or other abnormalities judged by the investigator as clinically significant.
  3. Positive result for any of the following: surface antigen or hepatitis B e antigen, virus antibody, Treponema pallidum antibody, or antigen/antibody combination test (HIV-Ag/Ab).
  4. Abnormal findings from ophthalmic examination (slit lamp, intraocular pressure, fundus photography) that are clinically significant.

    Medication History:

  5. Use of any drugs that inhibit or induce the drug-metabolizing enzyme within 30 days prior to the screening period.
  6. Use of any prescription drugs, over-the-counter drugs, herbal medicines, or food supplements (e.g., vitamins, calcium supplements) within 14 days prior to the screening period.

    Medical and Surgical History:

  7. History of any clinically serious disease or condition that the investigator believes may affect the trial results, including but not limited to circulatory, respiratory, endocrine, nervous, digestive, urinary, hematologic, immune, psychiatric, or metabolic diseases;
  8. History of dysphagia or any condition that may affect drug absorption, e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy, inflammatory bowel disease;
  9. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, arrhythmia, ventricular tachycardia, clinically symptomatic AV block, long QT syndrome, or family history of long QT syndrome (evidenced by genetic proof or sudden cardiac death of a close relative at a young age);
  10. Major surgery within 6 months prior to the screening period, or surgical incision not fully healed; Major surgery includes, but is not limited to, any procedure with significant bleeding risk, prolonged general anesthesia, incisional , or significant traumatic injury;
  11. Allergic constitution, e.g., known history of allergy to two or more substances; Or judged by the investigator as potentially allergic to the drug;
  12. Hemorrhoids or perianal diseases with regular/ongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease.

    Lifestyle Habits:

  13. Habitual constipation or diarrhea;
  14. Alcoholism or regular alcohol consumption within 6 months prior to screening, i.e., alcohol intake exceeding 14 units per week (1 unit = 360 mL beer, or 45 mL spirit with 40% alcohol, or 150 mL wine), or a breath alcohol test result ≥20 mg/dL at screening, or inability to abstain from alcohol during the trial period;
  15. Smoking >5 cigarettes per day or habitual use of nicotine-containing products within 3 months prior to screening, or inability to abstain during the trial period;
  16. Drug abuse or use of soft drugs (e.g., cannabis) within 3 months prior to screening, or use of hard drugs (e.g., amphetamines, phencyclidine) within 1 year prior to screening; Or positive urine screen for drugs of abuse during the screening period;
  17. Habitual consumption of grapefruit juice or excessive tea, coffee, and/or caffeinated beverages, and inability to abstain during the study period.

    Others:

  18. Participation in a radiolabeled drug trial within 1 year prior to screening, or participation in a 14C-labeled breath test within 3 months prior to screening;
  19. History of needle phobia or blood phobia, difficulty with blood collection, or inability to tolerate venous puncture;
  20. Participation in any other clinical trial (including drug and device trials) within 3 months prior to the screening period;
  21. Vaccination within 1 month prior to screening, or planned vaccination during the study period;
  22. Plan to father a child or donate sperm during the study period or within 1 year after study completion, or disagreement to use strict measures (see Appendix 1) for themselves and their partners during the study period and within 1 year after study completion;
  23. Blood loss or blood donation of ≥400 mL within 3 months prior to screening, or blood transfusion within 1 month;
  24. Any other factor that, in the investigator's opinion, makes the participant unsuitable for participation in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Single Dose Zorifertinib Group

    Drug: [14C]Zorifertinib Oral Formulation

Interventions

  • Drug[14C]Zorifertinib Oral Formulation

    Single oral administration of 200 mg/5 µCi \[¹⁴C\]Zorifertinib in healthy male subjects under fasting condition

06

What researchers measure

Primary outcomes

  1. Total radioactive recovery and cumulative total radioactive recovery in urine and feces at each time interval

    Time frame: Pre-dose up to 312 hours after dosing, or until termination criteria met

  2. Percentage of total radioactivity exposure (%AUC), percentage of parent drug and its metabolites (%Dose), and metabolite identification

    Percentage of total radioactivity exposure (%AUC) accounted for by parent drug and its metabolites in plasma. Percentage of administered dose (%Dose) accounted for by parent drug and its metabolites in urine and faeces. Identification of metabolites in plasma, urine, and feces

    Time frame: Pre-dose up to 312 hours after dosing, or until termination criteria met

  3. Peak Plasma Concentration (Cmax)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  4. Time to Peak Concentration (Tmax)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  5. Area under the plasma concentration versus time curve (AUC)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  6. Elimination Half-Life (t1/2)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  7. Terminal Rate Constant (λz)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  8. Apparent Volume of Distribution (Vz/F)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  9. Apparent Clearance (CLz/F)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  10. Mean Residence Time (MRT)

    Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  11. Whole blood / plasma total radioactivity ratio

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  2. Time to Peak Concentration (Tmax)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  3. Area under the plasma concentration versus time curve (AUC)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  4. Elimination Half-Life (t1/2)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  5. Terminal Rate Constant (λz)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  6. Apparent Volume of Distribution (Vz/F)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  7. Apparent Clearance (CLz/F)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  8. Mean Residence Time (MRT)

    Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma

    Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met

  9. Incidence and severity of Adverse Events (AEs)

    All adverse events were classified according to the CTCAE (version: 6.0)

    Time frame: Pre-dose up to 312 hours after dosing, or until termination criteria met

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Jul 2026, 0 months.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 0 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 2, 2026
StartActual
Jul 6, 2026
Primary completionActual
Jul 18, 2026
CompletionActual
Aug 3, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07620951
Lead sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jul 6, 2026
Primary completion
Jul 18, 2026
Completion
Aug 3, 2026
Last update
Sep 22, 2026

Study contacts

Liyan Miao, Ph.D.
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion